{
  "data_version": "1.0.0",
  "generated_at": "2025-08-25T03:29:16.179937Z",
  "items": [
    {
      "id": "acvim-se-cs-2024",
      "org": "ACVIM",
      "title": "Consensus Statement on the Management of Status Epilepticus and Cluster Seizures in Dogs and Cats",
      "year": 2024,
      "doi": "10.1111/jvim.16928",
      "pdf_url": "https://onlinelibrary.wiley.com/doi/10.1111/jvim.16928",
      "species": [
        "dog",
        "cat"
      ],
      "systems": [
        "neurology",
        "emergency"
      ],
      "conditions": [
        "status epilepticus",
        "cluster seizures"
      ],
      "setting": [
        "Out-of-hospital (home)",
        "In-hospital (ER/GP/IM/Neuro)"
      ],
      "scope_in": [
        "Status epilepticus (SE) management",
        "Cluster seizures (CS) management",
        "Acute stabilization + short-term plans"
      ],
      "scope_out": [
        "Long-term epilepsy control outside the acute window",
        "Exotics/large animals",
        "Detailed ventilator protocols"
      ],
      "methods": "Panel of 5 specialists synthesized veterinary clinical and PK studies plus human data; most evidence in dogs, less in cats.",
      "grading_native": "ACVIM recommendation A/B/C/E (varies by species/route).",
      "normalized_grade": "A",
      "conflicts_of_interest": "Some disclosed (see paper). Off-label use noted.",
      "staging_system": "ILAE/IVETF timepoints: T1=5 min (start tx), T2=30 min (injury risk).",
      "thresholds": [
        {
          "name": "SE operational start (T1)",
          "value": "≥5 minutes continuous or ≥2 without recovery",
          "unit": "minutes",
          "how_measured": "clinical seizure duration/intervals"
        },
        {
          "name": "SE injury risk (T2)",
          "value": "≈30 minutes",
          "unit": "minutes",
          "how_measured": "clinical course"
        },
        {
          "name": "Cluster seizures",
          "value": ">2 seizures in 24 h",
          "unit": "count/24 h",
          "how_measured": "history/observation"
        }
      ],
      "diagnostics": {
        "first_line": [
          "Stabilize in parallel with antiseizure meds: airway/oxygen, temperature, glucose and electrolytes.",
          "Evaluate/treat hypoglycemia, electrolyte derangements, hypoxemia."
        ],
        "second_line": [
          "No mandated tests before escalation; proceed alongside seizure control per clinician judgment."
        ],
        "pitfalls": [
          "Do not delay treatment to obtain IV access; intranasal midazolam is acceptable first dose if IV not available."
        ],
        "do_not_do": []
      },
      "therapy": {
        "start_criteria": [
          "Initiate emergency treatment at T1 (≥5 min or recurrent without recovery)."
        ],
        "stop_hold_criteria": [],
        "first_line": [
          {
            "name": "Benzodiazepine (home/out-of-hospital)",
            "route": [
              "IN",
              "rectal",
              "IM"
            ],
            "detail": "IN midazolam preferred when feasible; rectal diazepam acceptable; IM midazolam only if caregiver trained.",
            "evidence": {
              "dog": "A",
              "cat": "E"
            }
          },
          {
            "name": "Benzodiazepine (in-hospital)",
            "route": [
              "IV",
              "IN",
              "IM"
            ],
            "detail": "IV midazolam or IV diazepam first-line; IN midazolam if IV not yet available; IM midazolam acceptable.",
            "evidence": {
              "dog": "A",
              "cat": "B"
            }
          },
          {
            "name": "If relapse after BZD boluses",
            "route": [
              "IV"
            ],
            "detail": "Start IV midazolam CRI; if unavailable, diazepam bolus + CRI (dogs).",
            "evidence": {
              "dog": "A",
              "cat": "B"
            }
          }
        ],
        "alternatives": [
          {
            "name": "Second-line antiseizure medications",
            "detail": "Levetiracetam (IV dogs/cats; IM/rectal where applicable) and Phenobarbital (dogs; cats). Consider fosphenytoin adjunct in dogs.",
            "evidence": {
              "dog": "A",
              "cat": "B"
            }
          },
          {
            "name": "Refractory (anesthetic tier)",
            "detail": "Ketamine ± CRI → Dexmedetomidine ± CRI → Propofol ± CRI (cats: CRI with caution).",
            "evidence": {
              "dog": "A",
              "cat": "C"
            }
          }
        ],
        "contraindications": [
          "Prefer midazolam over diazepam for CRI (adsorption to plastic; solvent issues).",
          "Propylene glycol in diazepam can cause phlebitis/hypotension; particular concern in cats."
        ],
        "interactions": [
          "Higher levetiracetam doses may be required in dogs on chronic phenobarbital (enzyme induction)."
        ],
        "adverse_effects": [
          "Cats: hepatotoxicity risk with longer-acting BZDs (clonazepam, clorazepate).",
          "Cats: propofol CRI—hematologic/clinical monitoring required; consider alternatives first."
        ]
      },
      "monitoring": {
        "schedule": [
          "Acute phase: continuous observation; if seizures relapse after BZD, move to CRI and add second-line early."
        ],
        "targets": [
          "Terminate seizures before T2 (~30 min). Maintain airway/oxygenation and normothermia; correct derangements."
        ],
        "escalation": [
          "Inadequate response to first-line BZD → add levetiracetam/phenobarbital (± fosphenytoin dogs).",
          "Refractory → anesthetic tier (ketamine → dexmedetomidine → propofol)."
        ],
        "client_notes": [
          "Known CS at home: give prescribed IN-midazolam or rectal diazepam at first event; seek ER if clustering persists.",
          "Levetiracetam ‘pulse’ can reduce further CS; use PO when safe (rectal/IM alternatives if not).",
          "Cats: avoid repeated/long BZD use without veterinary guidance; ER if >2 seizures/24 h."
        ]
      },
      "special_populations": [
        "Cats: weaker evidence base overall; many recommendations are expert-opinion (E).",
        "Cats: consider non-propofol anesthetics first for refractory cases.",
        "Home IM routes only if caregiver medically trained."
      ],
      "implementation": {
        "equipment": [
          "Intranasal delivery device can reduce time to first dose when IV access is delayed."
        ],
        "cost_notes": [
          "Some uses are off-label; document informed consent and comply with local regulations."
        ],
        "stewardship": []
      },
      "alignment": {
        "conflicts": [
          "Elevates intranasal midazolam over rectal diazepam at home (dogs A) vs older norms."
        ],
        "uncertainties": [
          "Limited feline trials; several cat recommendations graded as expert opinion.",
          "Dose specifics/CRI rates primarily in supplementary files."
        ]
      },
      "take_home": [
        {
          "text": "Treat SE at 5 minutes (T1); don’t wait for T2 (~30 min).",
          "grade": "A"
        },
        {
          "text": "Use IN-midazolam first-line when IV access is delayed; IV midazolam/diazepam are first-line in hospital.",
          "grade": "A"
        },
        {
          "text": "Add a longer-acting ASM early (LEV/PHB) to prevent refractoriness.",
          "grade": "B"
        }
      ],
      "one_screen_flow": [
        "Recognize SE: ≥5 min or ≥2 without recovery → act now.",
        "Stabilize & investigate in parallel (airway/O2, temp, glucose/electrolytes).",
        "Give BZD: Home—IN-MDZ preferred; Rectal DZP acceptable. Hospital—IV MDZ/DZP; IN-MDZ if IV delayed.",
        "If relapse/persistent: repeat bolus → start MDZ IV CRI (prefer MDZ over DZP for CRI).",
        "Start longer-acting ASM early: LEV and/or PHB; consider FOS (dogs).",
        "Refractory: Ketamine → Dexmedetomidine → Propofol (cats: CRI caution).",
        "Clusters: ‘pulse’ LEV ± BZD (cat caution); if persists, follow SE pathway."
      ],
      "review_next_by": "2027-12-31",
      "score": 86,
      "notes": {
        "dosing_availability": "Use supplementary tables for exact bolus/CRI doses and intervals.",
        "home_kit_tip": "Pre-dispensed IN-MDZ with written owner instructions reduces time to first dose."
      },
      "resources": [
        {
          "label": "Dose tables (supplement)",
          "url": "https://onlinelibrary.wiley.com/doi/10.1111/jvim.16928#support-information"
        }
      ],
      "_checksum": "9435b39525dc",
      "_source_file": "normalized"
    },
    {
      "id": "acvim-ui-dogs-2024",
      "org": "ACVIM",
      "title": "Consensus statement on diagnosis and management of urinary incontinence in dogs",
      "year": 2024,
      "doi": "10.1111/jvim.16975",
      "pdf_url": "https://onlinelibrary.wiley.com/doi/10.1111/jvim.16975",
      "species": [
        "dog"
      ],
      "systems": [
        "urology",
        "internal medicine",
        "surgery/endourology",
        "neurology",
        "radiology"
      ],
      "conditions": [
        "urinary incontinence",
        "USMI",
        "functional outflow obstruction",
        "mechanical outflow obstruction",
        "ectopic ureters",
        "detrusor hypocontractility"
      ],
      "setting": [
        "GP",
        "ER",
        "Internal Medicine",
        "Surgery/Endourology",
        "Neurology",
        "Radiology"
      ],
      "scope_in": [
        "Canine urinary incontinence: storage vs voiding disorders",
        "Initial work-up and first-/second-line management",
        "Peri-interventional testing and key procedural options"
      ],
      "scope_out": [
        "Cat urinary incontinence",
        "Detailed anesthetic/urodynamic protocols",
        "Comprehensive neurologic disease review"
      ],
      "methods": "Expert consensus with structured statements and panel votes; imaging/interventional sections co-reviewed with surgery/endourology. No targeted funding; panelists not compensated.",
      "grading_native": "Panel agreement percentage per statement (no GRADE).",
      "normalized_grade": "B",
      "conflicts_of_interest": "No targeted funding disclosed; acknowledgments note none beyond editorial assistance.",
      "staging_system": "Pattern-based classification: Storage disorders (e.g., USMI) vs Voiding disorders (FOO/MOO); use CUI-S at every visit.",
      "thresholds": [
        {
          "name": "Normal PVRV",
          "value": "0.2–1.0",
          "unit": "mL/kg",
          "how_measured": "2D ultrasound (V=L×W×H×0.52) or 3D bladder scanner; measure ≤10 min post-void"
        },
        {
          "name": "Abnormal PVRV",
          "value": ">3",
          "unit": "mL/kg",
          "how_measured": "As above; allow ample time for complete void"
        },
        {
          "name": "Catheter UTI risk",
          "value": "8–32",
          "unit": "% incidence",
          "how_measured": "Post-catheterization cultures"
        }
      ],
      "key_points": [
        "Measure PVRV in every incontinent dog by ultrasound within 10 minutes post-void; >3 mL/kg suggests a voiding disorder.",
        "Classify by pattern: storage (USMI) vs voiding (FOO/MOO) to drive targeted therapy.",
        "USMI first line: phenylpropanolamine (PPA) or estriol (spayed females); reassess in ~28 days and titrate.",
        "Prefer ultrasound over catheterization for PVRV to reduce infection risk; obtain UA and culture before procedures.",
        "Suspected ectopic ureters: cystoscopy ± fluoroscopy preferred—often diagnostic and therapeutic."
      ],
      "diagnostics": {
        "first_line": [
          "History + video of urination; CUI-S at every visit.",
          "Focused exam incl. rectal/urethral palpation; note bladder size pre- and post-void.",
          "Urinalysis + aerobic culture in all dogs with UI and before procedures; treat 5 days if culture-positive.",
          "Measure PVRV within 10 minutes of void (ultrasound preferred over catheterization)."
        ],
        "second_line": [
          "Survey abdominal radiographs including entire urethra if voiding disorder suspected.",
          "Retrograde urography ± cystoscopy for suspected voiding disorders (short urethra, strictures, diverticulae).",
          "Ectopic ureter work-up: ultrasound has limited sensitivity; cystoscopy ± fluoroscopy preferred; CT helpful if cystoscopy unavailable.",
          "Urodynamics (UPP/CMG/LPP/EMG) not required initially; consider in refractory cases or when ectopic ureters co-exist."
        ],
        "pitfalls": [
          "Pelvic bladder alone is neither specific nor sensitive for UI; do not anchor—investigate other causes (Sp ~68–75%, Sn ~65–76%).",
          "Sedation/anaesthesia alters MUCP and detrusor reflex during urodynamics; interpret cautiously."
        ],
        "do_not_do": [
          "Do not default to catheterization to measure PVRV; use ultrasound when available.",
          "Do not rely on pelvic bladder position to diagnose UI or decide therapy."
        ]
      },
      "therapy": {
        "start_criteria": [
          "Treat culture-positive UTI for 5 days, then reassess continence.",
          "Classify by PVRV + pattern: storage (e.g., USMI) vs voiding (FOO/MOO) and start targeted therapy."
        ],
        "stop_hold_criteria": [
          "Hold/adjust PPA if hypertension or adverse effects; monitor blood pressure.",
          "Hold alpha-blockers/benzodiazepines if hypotension or sedation limits function."
        ],
        "first_line": [
          {
            "name": "USMI — Phenylpropanolamine (PPA)",
            "dose": "2 mg/kg PO q8–12h (alternatives: 1.5 mg/kg q12h or 1 mg/kg q8h)",
            "duration": "Chronic; titrate to continence"
          },
          {
            "name": "USMI — Estriol (spayed females)",
            "dose": "2 mg/dog PO q24h ×7–14 d, then 1 mg/dog q24h (adjust to effect)",
            "duration": "Chronic; lowest effective dose"
          },
          {
            "name": "FOO — Alpha-blocker (tamsulosin or prazosin)",
            "dose": "Tamsulosin 0.4–0.8 mg/dog q24h (↑ to q12–8h if needed); Prazosin 0.5–3 mg/dog q8–12h",
            "duration": "Weeks; adjust to PVRV/clinical response"
          },
          {
            "name": "FOO — Skeletal muscle relaxant (diazepam)",
            "dose": "0.04–0.8 mg/kg/day divided q8–12h; give 30–60 min before voiding",
            "duration": "Short- to mid-term adjunct"
          }
        ],
        "alternatives": [
          {
            "name": "USMI — Urethral bulking (dextranomer/hyaluronic acid)",
            "notes": "Success >80%; recurrence common within 1 year; repeatable; monitor for UTIs/rare complications"
          },
          {
            "name": "USMI — Artificial urethral sphincter (AUS)",
            "notes": "Improved continence ~82–92%; risks: infection, migration, erosion; device adjustments needed"
          },
          {
            "name": "EU — Cystoscopic-guided laser ablation (CA-EU)",
            "notes": "Definitive for intramural EU; success 47–72% without meds; 77–82% with adjuncts/combined interventions"
          },
          {
            "name": "MOO — Urethral stent (malignant/benign strictures)",
            "notes": "Technical/clinical success ~97.6%; post-stent incontinence 26–41% depending on site"
          },
          {
            "name": "Detrusor hypocontractility — Bethanechol ± bladder relaxant",
            "notes": "Bethanechol 2.5–25 mg/dog q8–24h; consider oxybutynin 0.2–0.3 mg/kg q8–12h for overactive bladder"
          }
        ],
        "contraindications": [
          "Avoid estrogen therapies in prepubertal/intact females; use judiciously post-spay.",
          "Avoid PPA in uncontrolled hypertension/cardiac disease; monitor BP."
        ],
        "interactions": [],
        "adverse_effects": [
          "PPA: hypertension, agitation; Estriol: vulvar swelling/estrus signs; Alpha-blockers: hypotension/syncope; Diazepam: sedation/ataxia; Bethanechol: GI cramping/diarrhea."
        ]
      },
      "monitoring": {
        "schedule": [
          "After any medication change: recheck 1–4 weeks with CUI-S, exam, PVRV; BP if on PPA/alpha-blocker.",
          "Before cystoscopy/CA-EU/AUS/stenting: urinalysis + culture; if positive, start antimicrobials 24 h pre-anaesthesia."
        ],
        "targets": [
          "CUI-S improvement versus baseline.",
          "PVRV <1 mL/kg (ideal); ≤1.0 mL/kg normal; >3 mL/kg abnormal."
        ],
        "escalation": [
          "Persistent PVRV >3 mL/kg or worsening CUI-S → escalate diagnostics (retrograde studies ± cystoscopy) and consider FOO/MOO.",
          "Relapsing leakage despite optimized USMI meds → discuss bulking versus AUS."
        ],
        "client_notes": [
          "Give unhurried time to void fully; bring videos of urination if possible.",
          "Track leaks and water intake in a simple diary; report straining or hematuria.",
          "Expect reassessment after ~2–4 weeks of therapy changes; doses/devices may be adjusted."
        ]
      },
      "special_populations": [
        "Males: FOO may be more prevalent than USMI—exclude obstruction first.",
        "Neurologic flags (fecal incontinence, spinal pain, abnormal gait) → full neuro exam ± spinal MRI.",
        "Sedation/anaesthesia depresses MUCP and detrusor activity—interpret urodynamics cautiously."
      ],
      "implementation": {
        "equipment": [
          "2D/3D ultrasound (bladder scanner) for PVRV",
          "Radiography (include entire urethra)",
          "Retrograde contrast equipment ± fluoroscopy",
          "Cystoscopy/laser (for CA-EU and bulking)",
          "AUS kit",
          "Stenting equipment"
        ],
        "cost_notes": [
          "Cystoscopy/laser and AUS/stents require referral-level resources; bulking may need repeats within 12 months."
        ],
        "stewardship": [
          "Follow ISCAID: treat culture-positive UTI 5 days; avoid treating subclinical bacteriuria except around procedures; confirm negative culture when feasible prior to interventions."
        ]
      },
      "alignment": {
        "conflicts": [
          "Aligns with ISCAID UTI guidance on short (5-day) therapy and peri-procedural coverage."
        ],
        "uncertainties": [
          "Few prospective randomized trials; many recommendations are expert-based; optimal long-term monitoring cadence for specific therapies/devices is not definitively established."
        ]
      },
      "take_home": [
        {
          "text": "Measure PVRV in every incontinent dog (ultrasound ≤10 min post-void); >3 mL/kg suggests a voiding disorder—work up FOO/MOO.",
          "grade": "A"
        },
        {
          "text": "For USMI, start PPA (2 mg/kg q8–12h) or estriol in spayed females; reassess in ~28 days and titrate.",
          "grade": "A"
        },
        {
          "text": "Suspect ectopic ureters? Prefer cystoscopy (often diagnostic and therapeutic); use CT if cystoscopy unavailable.",
          "grade": "A"
        }
      ],
      "one_screen_flow": [
        "Confirm UI (history/video, CUI-S) → UA + culture → measure PVRV (ultrasound ≤10 min).",
        "If PVRV >3 mL/kg: radiographs incl. urethra → retrograde study ± cystoscopy; start FOO protocol (alpha-blocker ± diazepam) or manage MOO as indicated.",
        "If PVRV ≤1 mL/kg with leakage: USMI likely → start PPA or estriol (spayed female).",
        "Recheck 1–4 weeks: CUI-S, PVRV, BP (if on PPA/alpha-blocker).",
        "Refractory USMI: discuss bulking vs AUS.",
        "EU suspected/confirmed: cystoscopy/laser ablation; consider adjuncts.",
        "Before interventions: ensure negative culture or give peri-procedural antibiotics."
      ],
      "review_next_by": "2027-08-31",
      "score": 86,
      "_checksum": "328c9529304a",
      "_source_file": "normalized"
    },
    {
      "id": "acvim-itp-dx-2024",
      "org": "ACVIM",
      "title": "Consensus statement on the diagnosis of immune thrombocytopenia in dogs and cats",
      "year": 2024,
      "doi": "10.1111/jvim.16996",
      "pdf_url": "https://onlinelibrary.wiley.com/doi/10.1111/jvim.16996",
      "species": [
        "dog",
        "cat"
      ],
      "systems": [
        "hematology",
        "internal medicine",
        "emergency"
      ],
      "conditions": [
        "immune thrombocytopenia",
        "thrombocytopenia",
        "DIC",
        "pseudothrombocytopenia",
        "macrothrombocytopenia"
      ],
      "setting": [
        "GP",
        "Internal Medicine",
        "ER",
        "Hematology"
      ],
      "scope_in": [
        "Diagnostic approach and certainty levels for ITP in dogs and cats",
        "First- and second-line diagnostics, including hemostasis testing and comorbidity screening",
        "Interpretation pitfalls (pseudothrombocytopenia, breed macrothrombocytopenia), and when to consider bone marrow"
      ],
      "scope_out": [
        "Therapy/management (covered in a companion ACVIM treatment statement)",
        "Detailed transfusion protocols or immunosuppressive regimens"
      ],
      "methods": "PECO-framed questions with guideline statements; consensus process incorporating literature synthesis. Comorbidity recommendations scored with the IME (impact, magnitude, existence) metric.",
      "grading_native": "Per-statement Level of Evidence (Low/Moderate) and Strength of Recommendation (Weak/Strong). Example: PSAIG—LoE: Low; Strength: Weak.",
      "normalized_grade": "B",
      "conflicts_of_interest": "COI and off-label antimicrobial declarations provided (several authors report relationships; others declare none).",
      "staging_system": "Levels of diagnostic certainty for ITP (Possible → Probable/Diagnostic; optional 'with immunologic evidence'); separate dog and cat algorithms.",
      "thresholds": [
        {
          "name": "Algorithm entry",
          "value": "<100,000",
          "unit": "platelets/µL",
          "how_measured": "Automated count; confirm on blood smear and exclude clumping (cats prone)."
        },
        {
          "name": "Analyzer variability allowance",
          "value": "±25%",
          "unit": "relative error",
          "how_measured": "Between-method variability; repeat counts advised."
        },
        {
          "name": "Severe thrombocytopenia",
          "value": "<20,000–30,000",
          "unit": "platelets/µL",
          "how_measured": "Clinical risk zone where transfusion/major hemorrhage more likely in dogs."
        },
        {
          "name": "DIC screening — define abnormal",
          "value": "≥2 abnormal; PT/aPTT >25% over control",
          "unit": "panel-based",
          "how_measured": "Abnormal among PT, aPTT, D-dimer/FDP, fibrinogen, antithrombin; interpret relative to control."
        }
      ],
      "key_points": [
        "Verify true thrombocytopenia first: smear review to exclude clumping; if clumped, resample and recount.",
        "Expect analyzer intermethod variability (≈±25%); use consistent methodology for trending.",
        "Early coagulation testing helps separate consumption coagulopathies (e.g., DIC) from ITP.",
        "Use species-specific algorithms and assign diagnostic certainty; cats are especially prone to pseudothrombocytopenia.",
        "PSAIG, bone marrow, and platelet indices are not routine requirements for diagnosis."
      ],
      "diagnostics": {
        "first_line": [
          "Confirm true thrombocytopenia: blood film review to exclude clumps; if clumped, resample (non-EDTA acceptable) and recount.",
          "Repeat/replicate counts and interpret allowing ~±25% intermethod error.",
          "Coagulation testing (PT, aPTT ± D-dimer/FDP, fibrinogen, antithrombin) early to distinguish consumption coagulopathies (e.g., DIC) from ITP; treat ≥2 abnormal results as supportive of DIC; use >25% over control for PT/aPTT.",
          "Apply species-specific diagnostic algorithms (dogs vs cats) and assign diagnostic certainty; algorithms note cats frequently have pseudothrombocytopenia.",
          "Initiate comorbidity screening guided by consensus sections (e.g., vector-borne infections in dogs; FeLV/FIV in cats)."
        ],
        "second_line": [
          "Platelet surface–associated immunoglobulin (PSAIG): supportive only; not required for diagnosis. LoE: Low; Strength: Weak.",
          "Bone marrow evaluation: not routine; reserve for animals with ill-defined or additional cytopenias.",
          "Platelet indices (MPV/IPF/plateletcrit): adjunctive at best; not recommended for routine diagnostic/prognostic use (plateletcrit may rise before count in remission)."
        ],
        "pitfalls": [
          "Pseudothrombocytopenia from EDTA clumping (especially cats); always verify on smear/resample.",
          "Analyzer intermethod variability (~±25%); use consistent methodology for serial monitoring.",
          "Breed macrothrombocytopenia (e.g., Cavalier King Charles Spaniel): consider genetic testing early to avoid misclassification."
        ],
        "do_not_do": [
          "Do not rely on PSAIG as a standalone/routine test—diagnosis can be made without it.",
          "Do not perform routine bone marrow exams in straightforward isolated thrombocytopenia.",
          "Do not use MPV/IPF/plateletcrit as primary diagnostic or prognostic determinants."
        ]
      },
      "therapy": {
        "start_criteria": [
          "Outside the scope of this paper; see companion ACVIM treatment consensus."
        ],
        "stop_hold_criteria": [
          "Outside the scope of this paper."
        ],
        "first_line": [],
        "alternatives": [],
        "contraindications": [],
        "interactions": [],
        "adverse_effects": []
      },
      "monitoring": {
        "schedule": [
          "No fixed cadence specified; repeat platelet counts to confirm persistence and trend, using the same methodology per patient."
        ],
        "targets": [
          "Upward platelet trend indicates improvement; plateletcrit may increase before the automated count during remission."
        ],
        "escalation": [
          "Presence of melena is associated with poorer survival in dogs with ITP—treat as a red flag for disease severity."
        ],
        "client_notes": [
          "Monitor for new/worsening bleeding (petechiae, ecchymoses, melena).",
          "Cats may bleed less obviously (epistaxis uncommon); report lethargy/anorexia or subtle signs.",
          "Expect repeat blood checks to verify true low platelets and rule out clumping artifacts."
        ]
      },
      "special_populations": [
        "Cats: mucocutaneous bleeding less frequent; major hemorrhage relatively rare; epistaxis uncommon.",
        "Breeds with inherited macrothrombocytopenia (e.g., CKCS): early genetic testing recommended."
      ],
      "implementation": {
        "equipment": [
          "Hematology analyzer and blood film review capability",
          "Coagulation testing (PT, aPTT; access to D-dimer/FDP, fibrinogen, antithrombin if possible)",
          "Access to vector-borne/retroviral testing per regional risk"
        ],
        "cost_notes": [
          "PSAIG assays exist but are not standardized and are not required; consider as a send-out if pursued."
        ],
        "stewardship": [
          "Use comorbidity testing to avoid unnecessary immunosuppression when a non-immune cause is likely (e.g., DIC/rodenticide)."
        ]
      },
      "alignment": {
        "conflicts": [
          "Historically, some clinicians favored routine PSAIG or bone marrow—this consensus advises against routine use and allows diagnosis without immunologic testing when criteria are met."
        ],
        "uncertainties": [
          "Many statements are based on Low–Moderate LoE; platelet indices remain inconsistent; standardized thresholds for adjunctive tests are unsettled."
        ]
      },
      "take_home": [
        {
          "text": "Confirm true thrombocytopenia first (smear + repeat counts), allowing ~±25% intermethod error; cats are prone to clumping artifacts.",
          "grade": "A"
        },
        {
          "text": "Early coagulation testing (PT/aPTT ± D-dimer/FDP, fibrinogen, antithrombin) helps separate DIC/rodenticide from ITP; treat ≥2 abnormal results as supportive of DIC.",
          "grade": "A"
        },
        {
          "text": "Do not use PSAIG, bone marrow, or platelet indices as routine tests—diagnosis can be made without them in typical isolated thrombocytopenia.",
          "grade": "B"
        }
      ],
      "one_screen_flow": [
        "Confirm low platelets: <100,000/µL → review smear for clumps; if clumped, resample and recount.",
        "Quantify severity: if <30,000/µL (esp. <20,000/µL) treat as high risk for major bleeding/transfusion.",
        "Rule out consumption coagulopathy: PT, aPTT (>25% over control), D-dimer/FDP, fibrinogen, antithrombin; DIC if ≥2 abnormal.",
        "Assign diagnostic certainty via dog/cat algorithm; note species differences (cats often have pseudothrombocytopenia).",
        "Screen comorbidities based on risk (vector-borne in dogs; FeLV/FIV in cats).",
        "Only if atypical/additional cytopenias: consider bone marrow; avoid routine PSAIG/platelet indices.",
        "Monitor with consistent methodology; upward platelet trend (± earlier rise in plateletcrit) signals improvement."
      ],
      "review_next_by": "2026-12-31",
      "score": 77,
      "_checksum": "7b41fb8df526",
      "_source_file": "normalized"
    },
    {
      "id": "acvim-feline-ce-dx-2023",
      "org": "ACVIM",
      "title": "Consensus statement guidelines on diagnosing and distinguishing low-grade neoplastic from inflammatory lymphocytic chronic enteropathies in cats",
      "year": 2023,
      "doi": "10.1111/jvim.16690",
      "pdf_url": "https://onlinelibrary.wiley.com/doi/10.1111/jvim.16690",
      "species": [
        "cat"
      ],
      "systems": [
        "gastroenterology",
        "oncology",
        "imaging",
        "pathology",
        "internal medicine"
      ],
      "conditions": [
        "chronic enteropathy",
        "lymphocytic-plasmacytic enteritis (LPE)",
        "low-grade intestinal T-cell lymphoma (LGITL)"
      ],
      "setting": [
        "GP",
        "Internal Medicine",
        "Oncology",
        "Imaging",
        "Pathology"
      ],
      "scope_in": [
        "Definition and diagnostic differentiation of LPE vs LGITL",
        "Recommended diagnostic pathway for cats with chronic enteropathy",
        "Use/limits of imaging, histopathology, IHC, and PARR"
      ],
      "scope_out": [
        "Definitive treatment protocols for LPE/LGITL",
        "Prognostic staging systems",
        "Detailed anesthesia/ventilator protocols"
      ],
      "methods": "Literature review with panel consensus; statements graded by a modified evidence scheme (Levels I–III, O, E).",
      "grading_native": "Evidence levels I (highest) → III; O (other species); E (expert).",
      "normalized_grade": "B",
      "conflicts_of_interest": "Two authors affiliated with clonality-testing labs; other consultancies disclosed; authors state these did not influence outcomes.",
      "staging_system": "Terminology standardized as CE, LPE, and LGITL; no staging system.",
      "thresholds": [
        {
          "name": "Serum cobalamin — cellular deficiency likelihood",
          "value": "<209 (Se 51%, Sp 96% for ↑MMA); <290 (Se 74%, Sp 80%)",
          "unit": "ng/L",
          "how_measured": "Serum; MMA by serum biomarker",
          "note": "Low cobalamin more frequent in LGITL."
        },
        {
          "name": "Serum folate — limited utility",
          "value": "≥15.5 (reported Se 80%, Sp 100% in one study)",
          "unit": "μg/L",
          "how_measured": "Serum",
          "note": "Hemolysis can falsely elevate folate."
        }
      ],
      "key_points": [
        "Tissue diagnosis is the gold standard; high-quality mucosal biopsies usually suffice—jejunum is often affected and may need full-thickness access.",
        "Use IHC and PARR as adjuncts only; do not reclassify cases on clonality (PARR) alone.",
        "Abdominal ultrasound maps disease and nodes but cannot distinguish LPE from LGITL; a normal scan does not exclude pathology.",
        "Check cobalamin (± MMA) and folate; hypocobalaminemia is common—supplementation is safe and often indicated.",
        "Baseline work-up (CBC/Chem/UA/fecal/T4; FeLV/FIV as indicated; f-PLI, f-TLI) and comorbidity screening are essential."
      ],
      "diagnostics": {
        "first_line": [
          "CBC, chemistry, urinalysis, fecal, total T4; FeLV/FIV in at-risk cats.",
          "Abdominal ultrasound to localize lesions and screen nodes/other organs (cannot by itself distinguish LPE vs LGITL).",
          "f-PLI to assess pancreatitis; f-TLI to exclude EPI when indicated.",
          "Serum cobalamin ± MMA; folate (interpret with caveats)."
        ],
        "second_line": [
          "Histopathology on intestinal biopsies (gold standard). High-quality mucosal endoscopic biopsies or full-thickness; ensure orientation/quality. Jejunum often affected and not always reachable endoscopically.",
          "Immunohistochemistry panel (e.g., CD3, CD20/CD79a/PAX5, Ki-67, STAT5) to phenotype and support diagnosis.",
          "PARR (clonality) as adjunct—interpret only alongside clinical, histology, and IHC; do not reclassify on clonality alone."
        ],
        "pitfalls": [
          "No single biomarker/panel reliably differentiates LPE vs LGITL.",
          "Normal abdominal ultrasound does not exclude significant bowel pathology.",
          "Folate can be spuriously high with hemolysis.",
          "Clonal results can occur in non-neoplastic settings; integration required."
        ],
        "do_not_do": [
          "Do not use cytology to distinguish LPE vs LGITL (architecture needed).",
          "Do not rely on abdominal radiographs for diffuse CE.",
          "Do not reclassify cases based on PARR alone."
        ]
      },
      "therapy": {
        "start_criteria": [
          "Therapy selection beyond scope; confirm subtype by tissue diagnosis before classification-specific treatment."
        ],
        "stop_hold_criteria": [],
        "first_line": [],
        "alternatives": [],
        "contraindications": [],
        "interactions": [],
        "adverse_effects": []
      },
      "monitoring": {
        "schedule": [
          "Not prescriptive in this statement; follow disease-specific standards post-diagnosis."
        ],
        "targets": [
          "Correct hypocobalaminemia; reassess clinical response per CE standards."
        ],
        "escalation": [
          "Persistent/worsening signs despite diet/therapy → revisit histopathology/IHC/PARR integration; ambiguous cases acknowledged."
        ],
        "client_notes": [
          "Chronic GI signs (≥3 weeks) warrant full work-up; comorbidities are common.",
          "Imaging cannot confirm type—tissue is usually required.",
          "Low B12 is common; supplementation is safe and often indicated."
        ]
      },
      "special_populations": [
        "Common comorbidities: hyperthyroidism, CKD, pancreatitis, cholangitis, urolithiasis, HCM—plan work-up accordingly."
      ],
      "implementation": {
        "equipment": [
          "High-quality abdominal ultrasound",
          "Endoscopy or surgical biopsy capability",
          "Access to veterinary pathology with GI expertise",
          "IHC and PARR (external labs acceptable)"
        ],
        "cost_notes": [
          "IHC/PARR are send-outs; ensure proper FFPE handling and biopsy orientation to avoid repeat sampling."
        ],
        "stewardship": [
          "Avoid empiric immunosuppression before diagnostic sampling when possible."
        ]
      },
      "alignment": {
        "conflicts": [
          "WSAVA standards guide inflammation scoring but are not designed to differentiate LGITL vs LPE; ACVIM emphasizes multi-modal integration with IHC/PARR."
        ],
        "uncertainties": [
          "No imaging modality reliably distinguishes LPE vs LGITL; biomarker gaps remain; ambiguity persists despite advanced testing."
        ]
      },
      "take_home": [
        {
          "text": "Intestinal histopathology is the gold standard; high-quality mucosal biopsies usually suffice—jejunum involvement may need full-thickness access.",
          "grade": "B"
        },
        {
          "text": "Use IHC and PARR as adjuncts; never reclassify on clonality alone—integrate with histology and clinical context.",
          "grade": "B"
        },
        {
          "text": "Ultrasound maps disease but cannot distinguish LPE from LGITL; a normal scan does not exclude pathology.",
          "grade": "B"
        }
      ],
      "one_screen_flow": [
        "When to test → Cat with ≥3 weeks GI signs (rule out metabolic/endocrine/infectious; consider comorbidities).",
        "Baseline work-up → CBC/Chem/UA/fecal/T4; FeLV/FIV as indicated; f-PLI, f-TLI; cobalamin ± MMA and folate.",
        "Imaging → Abdominal ultrasound to localize; do not use imaging to distinguish LPE vs LGITL.",
        "Biopsy → Obtain adequate, well-oriented mucosal biopsies (duodenum ± ileum; consider full-thickness if needed; jejunum often involved).",
        "Ancillaries → Request GI IHC panel; add PARR; integrate all results (do not reclassify on PARR alone).",
        "Supportive → Treat hypocobalaminemia; then follow disease-specific therapy pathways (outside scope)."
      ],
      "review_next_by": "2027-12-31",
      "score": 71,
      "score_breakdown": {
        "Actionability_0.20": 3,
        "Specificity_0.15": 4,
        "Evidence_strength_0.15": 3,
        "Recency_0.10": 5,
        "Generalizability_0.10": 4,
        "Risk_clarity_0.10": 4,
        "Monitoring_clarity_0.10": 2,
        "Controversy_handling_0.05": 4,
        "Implementation_practicality_0.05": 4
      },
      "_checksum": "c2321ded2156",
      "_source_file": "normalized"
    },
    {
      "id": "acvim-itp-2024",
      "org": "ACVIM",
      "title": "Consensus statement on the treatment of immune thrombocytopenia in dogs and cats",
      "year": 2024,
      "doi": "10.1111/jvim.17079",
      "pdf_url": "https://onlinelibrary.wiley.com/doi/10.1111/jvim.17079",
      "species": [
        "dog",
        "cat"
      ],
      "systems": [
        "hematology",
        "internal medicine",
        "emergency"
      ],
      "conditions": [
        "immune thrombocytopenia",
        "primary ITP",
        "thrombocytopenia"
      ],
      "setting": [
        "GP",
        "ER/ICU",
        "Internal Medicine"
      ],
      "scope_in": [
        "Primary ITP (pITP) in dogs/cats",
        "Initial inpatient/outpatient management",
        "Remission, tapering, relapse monitoring"
      ],
      "scope_out": [
        "Detailed diagnostic criteria (see separate diagnosis manuscript)",
        "Non-immune thrombocytopenia",
        "Other IMHA/Evans syndromes"
      ],
      "methods": "Systematic evidence review feeding PICO questions; responses integrated by domain chairs; 2–3 Delphi rounds to consensus; 288 references; algorithms in Figures 2–3.",
      "grading_native": "Level of evidence (e.g., Low/Moderate), Strength of recommendation (e.g., Weak/Moderate/Strong), Degree of consensus (Delphi votes).",
      "normalized_grade": "B",
      "conflicts_of_interest": "Standard ACVIM/JVIM consensus process described; author list and oversight noted.",
      "staging_system": "Treatment response definitions (guided by ASH ITP): NR, PR, CR, Remission.",
      "thresholds": [
        {
          "name": "No response (NR)",
          "value": "<30,000",
          "unit": "platelets/µL",
          "how_measured": "CBC"
        },
        {
          "name": "Partial response (PR)",
          "value": "≥30,000 and <100,000 + >2× over baseline + no bleeding",
          "unit": "platelets/µL",
          "how_measured": "CBC"
        },
        {
          "name": "Complete response (CR)",
          "value": "≥100,000 + no bleeding",
          "unit": "platelets/µL",
          "how_measured": "CBC"
        },
        {
          "name": "Remission (off drug)",
          "value": "≥100,000 + no bleeding without treatment",
          "unit": "platelets/µL",
          "how_measured": "CBC"
        },
        {
          "name": "Lower-risk discharge threshold",
          "value": ">40–50,000 with bleeding controlled",
          "unit": "platelets/µL",
          "how_measured": "CBC + clinical bleed check"
        }
      ],
      "key_points": [
        "Start immunosuppressive glucocorticoids in suspected/diagnosed pITP; add single-dose vincristine (0.02 mg/kg IV) in bleeding dogs to speed platelet recovery.",
        "Use response thresholds (PR ≥30–<100k; CR ≥100k with no bleeding) to guide discharge and taper decisions.",
        "Avoid platelet antibody assays for monitoring; base decisions on CBC and bleeding status.",
        "Do not use routine platelet transfusions—reserve for life-threatening hemorrhage.",
        "Limit to ≤2 concurrent immunosuppressives; consider early second agent in large dogs to reduce steroid adverse effects.",
        "Taper steroids ~25% every 2–4 weeks once stable; recheck before each step; expect months to complete."
      ],
      "diagnostics": {
        "first_line": [
          "CBC with smear + focused physical exam; track mucocutaneous/ocular/GI bleeding and drug adverse effects.",
          "Use DOGiBAT bleeding assessment to standardize severity (referenced in algorithms)."
        ],
        "second_line": [
          "For relapse workup: history (drugs/travel), CBC/smear, chemistry/urinalysis; imaging and infectious/neoplastic testing as indicated; consider therapeutic drug monitoring."
        ],
        "pitfalls": [
          "Platelet antibody/megakaryocyte surface Ig assays: limited availability, lag time, lack of standardization—do not use for routine monitoring."
        ],
        "do_not_do": [
          "Do not base monitoring on platelet antibody assays.",
          "Routine platelet transfusion not recommended (no proven outcome benefit)."
        ]
      },
      "therapy": {
        "start_criteria": [
          "Diagnosed/suspected pITP with clinically relevant bleeding or severe thrombocytopenia (see algorithms)."
        ],
        "stop_hold_criteria": [
          "Escalate or hold taper if bleeding recurs or platelet count drops below PR/CR ranges; reassess for relapse triggers."
        ],
        "first_line": [
          {
            "name": "Glucocorticoids (immunosuppressive dose)",
            "dose": "per clinician protocol",
            "route": "PO/IV",
            "duration": "Months with taper per response",
            "notes": "First-line across species."
          },
          {
            "name": "Vincristine (dogs, add-on)",
            "dose": "0.02 mg/kg IV once",
            "route": "IV",
            "duration": "Single dose adjunct",
            "notes": "Moderately strong evidence for faster platelet recovery in bleeding dogs when added to steroids."
          }
        ],
        "alternatives": [
          {
            "name": "Second immunosuppressive (dogs)",
            "options": [
              "Azathioprine",
              "Modified cyclosporine",
              "Leflunomide",
              "Mycophenolate mofetil"
            ],
            "when": "Consider early in large dogs or when steroid adverse effects are likely; evidence low; avoid >2 concurrent immunosuppressives."
          },
          {
            "name": "Second immunosuppressive (cats)",
            "options": [
              "Chlorambucil",
              "Modified cyclosporine"
            ],
            "when": "Relapse on taper or steroid adverse effects/contraindications."
          },
          {
            "name": "hIVIg (adjunct)",
            "when": "Not recommended as monotherapy; selective use with glucocorticoids in severe bleeding."
          },
          {
            "name": "Platelet products",
            "when": "Reserve for severe/life-threatening bleeding; routine use not advised."
          },
          {
            "name": "Antifibrinolytics (EACA/TXA)",
            "when": "Life-threatening bleeding if DIC excluded; outcome benefit unproven; TXA may cause vomiting."
          }
        ],
        "contraindications": [
          "Avoid >2 concurrent immunosuppressive drugs; added toxicity without proven benefit.",
          "Avoid antiplatelet/anticoagulant drugs during severe thrombocytopenia."
        ],
        "interactions": [
          "Early addition of a second immunosuppressive can enable faster steroid taper in large dogs prone to steroid adverse effects."
        ],
        "adverse_effects": [
          "Glucocorticoids: GI signs, hepatopathy, calcinosis cutis, diabetes mellitus; risk increases with body weight—monitor and taper accordingly.",
          "Tranexamic acid: vomiting noted in cohorts."
        ]
      },
      "monitoring": {
        "schedule": [
          "Inpatient: Daily PE; CBC every 2–3 days until bleeding stops and platelets >40–50k/µL; intensify if bleeding/anemia/decline.",
          "Outpatient: With platelets >40–50k/µL and no bleeding—CBC/PE every 1–2 weeks ×1 month, then every 2–4 weeks until durable remission.",
          "During taper: PE/CBC/smear before any dose reduction; recheck in 1–3 weeks.",
          "Remission off drugs: Monthly PE+CBC ×3 months, then extend; check platelets before procedures/vaccines."
        ],
        "targets": [
          "Treatment goal: platelets ≥100,000/µL with no bleeding (on or off treatment)."
        ],
        "escalation": [
          "If platelets <40–50k/µL or bleeding recurs: increase monitoring, halt taper/adjust therapy per algorithms."
        ],
        "client_notes": [
          "Watch for petechiae, melena, epistaxis, lethargy; report immediately.",
          "Limit activity; soft food; avoid toys/procedures that can cause trauma.",
          "Expect frequent rechecks early; vaccination timing/number may change (one vaccine per visit; check platelets post-vaccine)."
        ]
      },
      "special_populations": [
        "Large dogs (>25 kg): higher steroid adverse-effect risk—consider earlier second agent to enable faster taper.",
        "Comorbidities needing faster steroid reduction: DM, HAC, urinary incontinence, severe cardiac disease, prior thromboembolism.",
        "Cats: For maintenance/relapse, consider chlorambucil or modified cyclosporine with glucocorticoids (weak evidence)."
      ],
      "implementation": {
        "equipment": [
          "CBC with smear; ability to hospitalize for bleeding control; access to blood bank (RBC ± platelet products helpful).",
          "Optional: DOGiBAT scoring; therapeutic drug monitoring if using cyclosporine; culture if UTI concern."
        ],
        "cost_notes": [
          "Platelet products are challenging and costly to produce—reserve for severe bleeding."
        ],
        "stewardship": [
          "Avoid >2 concurrent immunosuppressants; minimize iatrogenic harm (avoid IM/SQ injections; avoid noncompressible venipuncture).",
          "Avoid antithrombotic/antiplatelet drugs while severely thrombocytopenic."
        ]
      },
      "alignment": {
        "conflicts": [
          "Human ASH guidelines often prioritize TPO-RAs earlier; veterinary evidence for TPO-RAs is limited—consensus emphasizes steroids ± vincristine; platelet products infrequent."
        ],
        "uncertainties": [
          "Optimal steroid dosing schema not specified; best tapering of second agents unresolved.",
          "Platelet products improve counts but not proven to change outcomes; antifibrinolytics’ outcome benefit unproven."
        ]
      },
      "take_home": [
        {
          "text": "In bleeding dogs, add vincristine 0.02 mg/kg IV once to glucocorticoids for faster platelet recovery.",
          "grade": "A"
        },
        {
          "text": "Do not use platelet antibody assays for monitoring—base on CBC and bleeding status.",
          "grade": "B"
        },
        {
          "text": "Taper steroids ~25% every 2–4 weeks once stable; recheck before each step and expect months of therapy.",
          "grade": "C"
        }
      ],
      "one_screen_flow": [
        "Suspect/confirm pITP → start immunosuppressive glucocorticoids; in bleeding dogs, add vincristine 0.02 mg/kg IV once.",
        "Hospitalize if active bleeding: daily PE; CBC q2–3d; transfuse RBCs as needed; avoid IM/SQ; no antithrombotics; consider antifibrinolytics only for life-threatening bleeds (no DIC).",
        "Discharge when bleeding controlled and platelets >40–50k/µL; monitor weekly then every 2–4 weeks to durable remission.",
        "Begin taper once stable: reduce steroid dose ~25% every 2–4 weeks; recheck 1–3 weeks after each change; months to complete.",
        "Relapse? Re-evaluate (CBC/chem/UA ± imaging/infectious tests), resume prior effective dose or add/change second agent (dogs: azathioprine/cyclosporine/leflunomide/MMF; cats: chlorambucil or modified cyclosporine)."
      ],
      "review_next_by": "2027-08-24",
      "score": 85,
      "resources": [
        {
          "label": "Companion diagnosis consensus",
          "id": "acvim-itp-dx-2024"
        }
      ],
      "_checksum": "9f374c6c86fd",
      "_source_file": "normalized"
    },
    {
      "id": "acvim-lepto-2023",
      "org": "ACVIM",
      "title": "Updated ACVIM consensus statement on leptospirosis in dogs",
      "year": 2023,
      "doi": "10.1111/jvim.16903",
      "pdf_url": "https://onlinelibrary.wiley.com/doi/10.1111/jvim.16903",
      "species": [
        "dog"
      ],
      "systems": [
        "infectious disease",
        "nephrology",
        "emergency"
      ],
      "conditions": [
        "leptospirosis",
        "acute kidney injury",
        "leptospiral pulmonary hemorrhage syndrome"
      ],
      "setting": [
        "GP",
        "ER",
        "IM/Nephrology"
      ],
      "scope_in": [
        "Case definition (clinical + lab) and diagnostics",
        "Initial treatment (antimicrobials, supportive care, dialysis triggers)",
        "Prevention (vaccination), infection control & public health"
      ],
      "scope_out": [
        "Non-canine species (no feline vaccine)",
        "Advanced ventilator protocols; human treatment guidance"
      ],
      "methods": "ACVIM Board-selected expert panel; evidence-based synthesis with panel interpretive comments; membership input; JVIM editorial review. Uses Level of Agreement (LOA) per recommendation, not GRADE.",
      "grading_native": "Panel Level of Agreement (LOA); LOA ≥11/12 with direct evidence ≈ strong.",
      "normalized_grade": "B",
      "conflicts_of_interest": "Declared (honoraria/research support); no statement funding reported.",
      "staging_system": "Case definition by clinical criteria + laboratory criteria (supportive vs confirmatory).",
      "thresholds": [
        {
          "name": "MAT single titer (supportive)",
          "value": "≥1:800",
          "unit": "reciprocal dilution",
          "how_measured": "Microscopic agglutination test (acute-phase serum); single titer is supportive only."
        },
        {
          "name": "MAT convalescent rise (confirmatory)",
          "value": "≥4-fold increase",
          "unit": "fold-rise",
          "how_measured": "Paired sera 7–14 days apart."
        },
        {
          "name": "High MAT titer context",
          "value": "≥1:3200 suggests active disease",
          "unit": "reciprocal dilution",
          "how_measured": "Interpret with clinical signs; not definitive alone."
        },
        {
          "name": "NAAT (PCR) confirmatory",
          "value": "Leptospira DNA in blood",
          "unit": "qualitative",
          "how_measured": "EDTA blood before antibiotics, if possible."
        },
        {
          "name": "NAAT (PCR) supportive",
          "value": "Leptospira DNA in urine",
          "unit": "qualitative",
          "how_measured": "Urine shedding often begins ~7–10 days post-infection; collect blood + urine when possible."
        },
        {
          "name": "Vaccination primary series",
          "value": "2 doses 4 weeks apart, start ≥12 weeks of age",
          "unit": "doses & weeks",
          "how_measured": "Manufacturer-licensed bacterins."
        },
        {
          "name": "Vaccination booster",
          "value": "Annual",
          "unit": "months",
          "how_measured": "Label and duration studies."
        }
      ],
      "key_points": [
        "Start antimicrobials promptly in compatible cases: hospital IV ampicillin then transition to doxycycline; outpatient doxycycline if mild.",
        "Diagnose with paired testing: NAAT (blood+urine) ideally pre-antibiotics; confirm with ≥4-fold MAT rise at 7–14 days.",
        "Isolate and use PPE; counsel owners on zoonotic risk and urine handling.",
        "Consider dialysis for anuric/oliguric AKI or uncontrolled azotemia; monitor UOP, BP, electrolytes, creatinine daily.",
        "Vaccinate annually after recovery; use the broadest serovar coverage available."
      ],
      "diagnostics": {
        "first_line": [
          "CBC/Chem/UA and blood pressure; thoracic imaging if respiratory signs; abdominal ultrasound for differential support.",
          "MAT on acute serum (do not rule in/out from a single titer).",
          "NAAT (PCR) on EDTA blood and urine (collect before antibiotics when possible).",
          "POC IgM/IgG immunoassays early in disease; a negative does not exclude disease."
        ],
        "second_line": [
          "Convalescent MAT at 7–14 days to document ≥4-fold rise.",
          "Repeat NAAT if initial negative but suspicion remains (phase-dependent).",
          "Culture/histology via reference labs only; not routine."
        ],
        "pitfalls": [
          "Single MAT positive is not diagnostic; post-vaccinal titers can be high.",
          "MAT serogroup reactions do not identify the infecting serovar.",
          "Blood NAAT is confirmatory; urine NAAT supportive; both can be negative depending on timing/antibiotics.",
          "Thoracic radiographs can underestimate pulmonary hemorrhage vs CT; patterns evolve."
        ],
        "do_not_do": [
          "Do not rely on dark-field microscopy or non-reference culture in practice.",
          "Do not choose vaccines based on MAT serosurveys when multiple products exist."
        ]
      },
      "therapy": {
        "start_criteria": [
          "Begin antimicrobials promptly in compatible illness with supportive tests (e.g., POC positive, NAAT-positive urine) while awaiting convalescent serology."
        ],
        "stop_hold_criteria": [
          "Transition from IV bacteremia-phase therapy to oral doxycycline after 24–48 h when stable/tolerating PO; hold/switch if significant GI intolerance."
        ],
        "first_line": [
          {
            "name": "Ampicillin (hospitalized, bacteremic phase)",
            "dose": "20–30 mg/kg IV q8h",
            "duration": "24–48 h then switch",
            "notes": "Clear bacteremia; transition to doxycycline to eliminate renal carriage."
          },
          {
            "name": "Doxycycline (carrier clearance & outpatients)",
            "dose": "5 mg/kg PO q12h ×14 d",
            "duration": "14 d",
            "notes": "Eliminates renal shedding; also recommended prophylaxis for exposed cohoused dogs."
          }
        ],
        "alternatives": [
          {
            "name": "Minocycline (if doxy intolerance/unavailable)",
            "dose": "2 mg/kg PO q12h ×14 d",
            "notes": "Alternative tetracycline per panel."
          },
          {
            "name": "Broad-spectrum β-lactam or fluoroquinolone",
            "dose": "per label",
            "notes": "For initial stabilization if ampicillin not feasible; switch to doxycycline after 24–48 h."
          }
        ],
        "contraindications": [
          "Use immunosuppressives with caution; no evidence of benefit in leptospiral pulmonary hemorrhage syndrome (LPHS).",
          "Transfusion seldom indicated unless clear need."
        ],
        "interactions": [],
        "adverse_effects": [
          "Doxycycline GI irritation—give with food/water; monitor vomiting; adjust if intolerance."
        ]
      },
      "monitoring": {
        "schedule": [
          "Inpatient daily: hydration, urine output, electrolytes, creatinine, acid-base; BP at least daily; thoracic imaging if respiratory signs evolve.",
          "Convalescent testing at 7–14 days to confirm ≥4-fold MAT rise; repeat NAAT guided by timing/antibiotics."
        ],
        "targets": [
          "Urine output >1.3 mL/kg/h (favorable).",
          "Stabilizing creatinine/electrolytes; improving clinical signs."
        ],
        "escalation": [
          "Consider extracorporeal kidney support for anuria/oliguria or uncontrolled azotemia; negative prognostic factors include anuria, respiratory complications, DIC, pancreatitis, higher IRIS AKI grade.",
          "Worsening respiratory signs → oxygen/advanced care; radiographs may underestimate LPHS—consider CT if unstable course."
        ],
        "client_notes": [
          "Avoid urine contact; gloves/eye protection for cleanup; discuss zoonosis and provide credible public-health resources.",
          "Household dogs: consider prophylactic doxycycline 5 mg/kg PO q12h ×14 d with acute/convalescent titers.",
          "Vaccinate annually after recovery; exposure risk persists and natural immunity is uncertain."
        ]
      },
      "special_populations": [
        "Shelters: initial + booster ~3 weeks apart at intake due to shedding risk.",
        "Small breeds: higher odds of post-vaccination AEs across vaccines, but lepto bacterins are not worse than core vaccines overall.",
        "Cats: no approved leptospiral vaccines; canine biologics are not recommended."
      ],
      "implementation": {
        "equipment": [
          "POC immunoassay kits (IgM/IgG)",
          "Access to NAAT (PCR) for blood/urine",
          "Isolation/PPE supplies",
          "Dialysis access (referral)"
        ],
        "cost_notes": [
          "Dialysis is high-cost; use outcome scores to counsel."
        ],
        "stewardship": [
          "Prefer penicillin-class → doxycycline sequence; avoid unnecessary broad-spectrum agents; vaccinate broadly to reduce community risk."
        ]
      },
      "alignment": {
        "conflicts": [
          "ACVIM supports annual vaccination for all dogs (universal) vs some risk-based local practices; recommends broadest serovar coverage; avoid MAT serosurveys to choose products."
        ],
        "uncertainties": [
          "Duration of natural-infection immunity and cross-protection; disease incidence in fully vaccinated dogs; extent/duration of urinary shedding in exposed cohabitants."
        ]
      },
      "take_home": [
        {
          "text": "Treat early: ampicillin 20–30 mg/kg IV q8h for 24–48 h, then doxycycline 5 mg/kg PO q12h ×14 d to eliminate renal shedding.",
          "grade": "A"
        },
        {
          "text": "Paired testing: NAAT (blood+urine) ideally pre-antibiotics; confirm with ≥4-fold MAT rise at 7–14 days.",
          "grade": "A"
        },
        {
          "text": "Vaccinate annually after a 2-dose puppy series using the broadest serovar coverage available.",
          "grade": "B"
        }
      ],
      "one_screen_flow": [
        "Suspect lepto (AKI ± hepatic ± LPHS) → isolate & PPE.",
        "Same visit: CBC/Chem/UA; NAAT (EDTA blood + urine pre-antibiotics); MAT (acute serum); optional POC IgM/IgG.",
        "Start antimicrobials now: ampicillin IV (hospital) or doxycycline PO if mild/outpatient.",
        "Supportive care: fluids to euvolemia; antiemetics; monitor urine output & BP; escalate to dialysis if anuric/oliguric.",
        "7–14 d: convalescent MAT (aim ≥4-fold rise). If initial NAAT negative but suspicion high, repeat per timing.",
        "Discharge instructions: urine precautions; vaccinate after recovery; counsel household prophylaxis."
      ],
      "review_next_by": "2028-12-31",
      "score": 88,
      "_checksum": "92430f45d305",
      "_source_file": "normalized"
    }
  ]
}